Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer.

At the end of treatment in the clinical trial, CN was 2.43 and E401G VAF was 10.9%, with a slightly increasing trend reflecting disease progression (Fig. 1 A).

also in 801 other papers